Sponsored

Chimeric Therapeutics (ASX:CHM) September Quarter: Progress in Cancer Trials and Strategic Partnerships

November 12, 2024 12:01 AM GMT | By Aditi Saha
 Chimeric Therapeutics (ASX:CHM) September Quarter: Progress in Cancer Trials and Strategic Partnerships
Image source: Company update

Highlights

  • Chimeric Therapeutics dosed the first patient in its Phase 1/2 clinical trial for CHM CDH17 CAR-T cell therapy.
  • In September, Chimeric announced collaboration with Achieve Clinics to expand access to CHM CDH17 through Achieve’s PRO-Aph™ process.
  • The company formed a partnership with Cell Therapies Pty Ltd to explore the manufacturing of its CAR T-cell therapies in Australia.
  • Chimeric’s CHM CORE-NK Phase 1b combination trial reported a complete response in an acute myeloid leukemia patient.

Chimeric Therapeutics Limited (ASX:CHM) achieved significant milestones in the September 2024 quarter, including the enrollment and dosing of the first patient in the CHM CDH17 Phase 1/2 trial. This trial aims to guide dose selection, with plans for Phase 2 expansion targeting specific cancer cohorts.

Chimeric also expanded the patient access to CHM CDH17 through a partnership with Achieve Clinics and teamed up with Cell Therapies Pty Ltd to explore CAR T cell manufacturing in Australia.

Phase 1/2 Trial for CHM CDH17 CAR-T Advances

In August, Chimeric Therapeutics dosed the first patient in its Phase 1/2 clinical trial for CHM CDH17 CAR-T cell therapy at the Sarah Cannon Research Institute in Nashville, Tennessee. This trial is enrolling patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours at multiple US cancer centres.

The University of Pennsylvania (Penn) also began enrolling patients for the trial, with additional sites anticipated to open by the end of 2024.

In September, the company announced a collaboration with Achieve Clinics to expand access to CHM CDH17 through Achieve’s PRO-Aph™ process, which is expected to improve cell collection early in the cancer treatment process and enhance patient recruitment and trial timelines.

Chimeric Partners with Cell Therapies

Chimeric Therapeutics has announced a strategic partnership with Cell Therapies Pty Ltd to explore the manufacturing of its CAR T-cell therapies in Australia.  This collaboration aims to provide Australian patients with access to Chimeric’s cutting-edge clinical trials, focused on cancer treatment through CAR T and NK cell therapies. With four clinical trials currently underway in the US, Chimeric is also considering the addition of Australian sites to broaden patient access.

Post-quarter, Chimeric reported a notable achievement in its CHM CORE-NK Phase 1b combination trial: an Acute Myeloid Leukemia (AML) patient achieved a complete response. Additionally, the company secured commitments for a AU$5 million capital raise.

Chimeric also received AU$1.56 million from Endpoints Capital, under a facility linked to the company’s anticipated FY24 Research and Development Tax Incentive (RDTI). The funds will support the clinical trial pipeline.

The share price of CHM was AU$0.010 as on 11 November 2024.

 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


AI on the Rise: A Look at Top AI Companies and Their Stocks

Send OTP Resend OTP in 30s

Sponsored Articles


Investing Ideas

Previous Next